Indoco Remedies Ltd 2017 AR2
The report highlights Indoco Remedies Ltd.'s financial and operational performance for the fiscal year 2016-2017. Despite regulatory challenges in international markets and domestic policy changes, the company registered an 8.8% sales growth. Key achievements include the acquisition of a manufacturing facility in Baddi and successful USFDA audits of its clinical research division, AnaCipher, with zero observations. The company also expanded its CSR initiatives under the 'Sumati Sangopan' banner, focusing on healthcare, education, and environmental sustainability.
Company: Indoco Remedies Ltd
Sector: Manufacturing
Country: India
Year: 2017
Type: AR2
Pages: 224
Back to company
Indoco Remedies Ltd
Annual Report
The report highlights Indoco Remedies Ltd.'s financial and operational performance for the fiscal year 2016-2017. Despite regulatory challenges in international markets and domestic policy changes, the company registered an 8.8% sales growth. Key achievements include the acquisition of a manufacturing facility in Baddi and successful USFDA audits of its clinical research division, AnaCipher, with zero observations. The company also expanded its CSR initiatives under the 'Sumati Sangopan' banner, focusing on healthcare, education, and environmental sustainability.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees